NASDAQ:ENTX - Nasdaq - IL0011429839 - Common Stock - Currency: USD
Taking everything into account, ENTX scores 3 out of 10 in our fundamental rating. ENTX was compared to 553 industry peers in the Biotechnology industry. ENTX has a great financial health rating, but its profitability evaluates not so good. ENTX has a expensive valuation and it also scores bad on growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -46.72% | ||
ROE | -52.07% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 4.04% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | 14.85 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 13.07 | ||
Quick Ratio | 13.07 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
1.86
-0.05 (-2.62%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 379.09 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 4.36 | ||
P/tB | 4.36 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -46.72% | ||
ROE | -52.07% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 4.04% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 26.83% | ||
Cap/Sales | 4.93% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 13.07 | ||
Quick Ratio | 13.07 | ||
Altman-Z | 14.85 |